Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)

Conditions

Hyperlipidemia

Keywords

Hyperlipidemia, coronary heart disease, prevention, stroke, pravastatin

Brief summary

To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.

Detailed description

MEGA Study is the first prospective, randomized, controlled trial conducted in Japan to evaluate the primary preventive effect of pravastatin against CHD in daily clinical practice. Because the dose of pravastatin used in the MEGA Study was 10-20 mg/day, which is consistent with the approved doses in Japan and lower than the doses used in previous large-scale clinical trials.

Haruo Nakamura, Kyoichi Mizuno, Kyoichi Mizuno

Lipids in Health and Disease2014-08-184 citations

10.1186/1476-511x-13-133

Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level ≥100 mg/dL increases cardiovascular risk.

Tajima N, Kurata H, Ohashi Y, Mizuno K, Nakamura H.

2011-10-01

10.1111/j.2040-1124.2011.00121.x

Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).

Nakaya N, Mizuno K, Ohashi Y, Teramoto T, Yokoyama S, Hirahara K, Mizutani M, Nakamura H, MEGA Study Group.

2011-09-0129 citations

10.2165/11595620-000000000-00000

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, MEGA Study Group.

2006-09-01650 citations

10.1016/s0140-6736(06)69472-5

Interventions

BEHAVIORALDiet

DRUGDiet+pravastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

No

Inclusion criteria

* TC:220～270mg/dl * Male: 40-70 years old/ female: postmenopausal-70 years old * \<40kg in weight

Exclusion criteria

* FH * History of CHD(angina, MI, post-PTCA/CABG, etc.) * History of CVA(stroke, TIA, etc.) * Underlying malignant tumor

Design outcomes

Primary

Measure	Time frame
Coronary Heart Disease(CHD)[fatal/non-fatal MI, sudden/cardiac death, angina, revascularization]	—

Secondary

Measure	Time frame
Stroke, cerebrovascular infarction(CI), CHD+CI, all cardiovascular events, total mortality	—

Outcome results

None listed